Omeros corporation reports first quarter 2021 financial results

Seattle--(business wire)--omeros corporation (nasdaq: omer), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced recent highlights and developments as well as financial results for the first quarter ended march 31,
OMER Ratings Summary
OMER Quant Ranking